Table of Contents Table of Contents 2 Introduction 4 Neuroendocrine Tumors - Overview 5 Neuroendocrine Tumors - Therapeutics Development 6 Neuroendocrine Tumors - Therapeutics Assessment 17 Neuroendocrine Tumors - Companies Involved in Therapeutics Development 29 Neuroendocrine Tumors - Drug Profiles 52 Neuroendocrine Tumors - Dormant Projects 398 Neuroendocrine Tumors - Discontinued Products 400 Neuroendocrine Tumors - Product Development Milestones 401 Appendix 413

List of Tables Number of Products under Development for Neuroendocrine Tumors, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Neuroendocrine Tumors - Pipeline by AbbVie Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications SA, H1 2017 Neuroendocrine Tumors - Pipeline by Aegis Therapeutics LLC, H1 2017 Neuroendocrine Tumors - Pipeline by Amgen Inc, H1 2017 Neuroendocrine Tumors - Pipeline by AstraZeneca Plc, H1 2017 Neuroendocrine Tumors - Pipeline by AVEO Pharmaceuticals Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Neuroendocrine Tumors - Pipeline by Bristol-Myers Squibb Company, H1 2017 Neuroendocrine Tumors - Pipeline by Celgene Corp, H1 2017 Neuroendocrine Tumors - Pipeline by Cleave Biosciences Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Neuroendocrine Tumors - Pipeline by Dauntless Pharmaceuticals Inc, H1 2017 Neuroendocrine Tumors - Pipeline by DexTech Medical AB, H1 2017 Neuroendocrine Tumors - Pipeline by Eisai Co Ltd, H1 2017 Neuroendocrine Tumors - Pipeline by Eli Lilly and Company, H1 2017 Neuroendocrine Tumors - Pipeline by Esperance Pharmaceuticals Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Exelixis Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Foresee Pharmaceuticals LLC, H1 2017 Neuroendocrine Tumors - Pipeline by Hutchison China MediTech Ltd, H1 2017 Neuroendocrine Tumors - Pipeline by Ignyta Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Ipsen SA, H1 2017 Neuroendocrine Tumors - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 Neuroendocrine Tumors - Pipeline by Karyopharm Therapeutics Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Mateon Therapeutics Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Merck & Co Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Midatech Pharma Plc, H1 2017 Neuroendocrine Tumors - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 Neuroendocrine Tumors - Pipeline by MolMed SpA, H1 2017 Neuroendocrine Tumors - Pipeline by Northwest Biotherapeutics Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Novartis AG, H1 2017 Neuroendocrine Tumors - Pipeline by OctreoPharm Sciences GmbH, H1 2017 Neuroendocrine Tumors - Pipeline by Peptron Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Pfizer Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Pharma Mar SA, H1 2017 Neuroendocrine Tumors - Pipeline by Progenics Pharmaceuticals Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Regulaxis SAS, H1 2017 Neuroendocrine Tumors - Pipeline by Strongbridge Biopharma plc, H1 2017 Neuroendocrine Tumors - Pipeline by Taiwan Liposome Company Ltd, H1 2017 Neuroendocrine Tumors - Pipeline by Tarveda Therapeutics Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Threshold Pharmaceuticals Inc, H1 2017 Neuroendocrine Tumors - Pipeline by Vascular Biogenics Ltd, H1 2017 Neuroendocrine Tumors - Pipeline by Xencor Inc, H1 2017 Neuroendocrine Tumors - Dormant Projects, H1 2017 Neuroendocrine Tumors - Dormant Projects, H1 2017 (Contd..1), H1 2017 Neuroendocrine Tumors - Discontinued Products, H1 2017 List of Figures Number of Products under Development for Neuroendocrine Tumors, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products by Top 10 Targets, H1 2017 Number of Products by Stage and Top 10 Targets, H1 2017 Number of Products by Top 10 Mechanism of Actions, H1 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 Number of Products by Routes of Administration, H1 2017 Number of Products by Stage and Routes of Administration, H1 2017 Number of Products by Top 10 Molecule Types, H1 2017 Number of Products by Stage and Top 10 Molecule Types, H1 2017

AbbVie Inc Advanced Accelerator Applications SA Aegis Therapeutics LLC Amgen Inc AstraZeneca Plc AVEO Pharmaceuticals Inc Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corp Cleave Biosciences Inc Crinetics Pharmaceuticals Inc Daiichi Sankyo Company Ltd Dauntless Pharmaceuticals Inc DexTech Medical AB Eisai Co Ltd Eli Lilly and Company Esperance Pharmaceuticals Inc Exelixis Inc Foresee Pharmaceuticals LLC Hutchison China MediTech Ltd Ignyta Inc Ipsen SA Jiangsu Hengrui Medicine Co Ltd Karyopharm Therapeutics Inc Lexicon Pharmaceuticals Inc Mateon Therapeutics Inc Merck & Co Inc Midatech Pharma Plc Millennium Pharmaceuticals Inc MolMed SpA Northwest Biotherapeutics Inc Novartis AG OctreoPharm Sciences GmbH Peptron Inc Pfizer Inc Pharma Mar SA Progenics Pharmaceuticals Inc Provectus Biopharmaceuticals Inc Regulaxis SAS Strongbridge Biopharma plc Taiwan Liposome Company Ltd Tarveda Therapeutics Inc Threshold Pharmaceuticals Inc Vascular Biogenics Ltd Xencor Inc